Patents by Inventor Abdelkrim Habi

Abdelkrim Habi has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20040171534
    Abstract: The present invention relates to chimeric fatty body-GRF analogs with increased biological potency, their application as anabolic agents and in the diagnosis and treatment of growth hormone deficiencies. The chimeric fatty body-GRF analogs include an hydrophobic moiety (tail), and can be prepared, either by anchoring at least one hydrophobic tail to the GRF, in the chemical synthesis of GRF. The GRF analogs of the present invention are biodegradable, non-immunogenic and exhibit an improved anabolic potency with a reduced dosage and prolonged activity.
    Type: Application
    Filed: August 7, 2002
    Publication date: September 2, 2004
    Applicant: Theratechnologies, Inc.
    Inventors: Denis Gravel, Abdelkrim Habi, Paul Brazeau
  • Patent number: 6762160
    Abstract: This invention relates to compositions for removing biofilms from contaminated surfaces. The compositions minimally comprise a detergent and a salt or a salt-forming acid. Preferably, the compositions comprise a detergent and a salt-forming acid, to provide salts and acids in equilibrium, in such a way that the biofilm is rapidly dismantled and removed in such an environment. The compositions may also comprise a bactericide, for destroying bacteria.
    Type: Grant
    Filed: May 9, 2001
    Date of Patent: July 13, 2004
    Assignee: Universite de Montreal
    Inventors: Jean Barbeau, Denis Gravel, Abdelkrim Habi
  • Publication number: 20040127412
    Abstract: The present invention relates to a GLP-1 peptide having the following formula, or a pharmaceutically acceptable salt thereof:
    Type: Application
    Filed: September 25, 2003
    Publication date: July 1, 2004
    Applicant: THERATECHNOILOGIES INC.
    Inventors: Denis Gravel, Krishna Peri, Thierry Abribat, Abdelkrim Habi
  • Publication number: 20030212126
    Abstract: Novel compounds of the formula (I) wherein: one of R1, R2, R3, R4, and (R10)n represents an halogen atom and each of the remaining R1, R2, R3, R4, and each of the remaining R10 group is independently selected in the group constituted by hydrogen, halogen atoms, an amino, acylamino, dialkylamino, cycloalkylamino, azacycloalkyl, alkylcycloalkylamino, aroylamino, diarylamino, arylalkylamino, aralkylamino, alkylaralkylamino, arylaralkylamino, hydroxy, alkoxy, aryloxy, aralkyloxy, mercapto, alkylthio, arylthio, aralkylthio, carboxyl, alkoxycarbonyl, aryloxycarbonyl, aralkoxycarbonyl, carbamoyl, alkylcarbamoyl, dialkylcarbamoyl, cyano, hydroxysulfonyl, amidosulfonyl, dialkylamidosulfonyl, arylalkylamidosulfonyl, formyl, acyl, aroyl, alkyl, alkylene, alkenyl, aryl, aralkyl, vinyl, alkynyl group and by the corresponding substituted groups; —m=0-1; n=1-4, A is nil, O, or NH; R9 represents an alkylene group; —Z is H, amino, dialkylamino, or trialkylamino salt; X—is an anion; R5, R6, R7 a
    Type: Application
    Filed: May 30, 2003
    Publication date: November 13, 2003
    Inventors: Abdelkrim Habi, Denis Gravel, Luc Villenueve, Hongsheng Su, Marc Vaillancourt
  • Publication number: 20030204063
    Abstract: The present invention is concerned with modified biological peptides providing increased potency, prolonged activity and/or increased half-life thereof. The modification is made via coupling through an amide bond with at least one conformationally rigid substituent, either at the N-terminal of the peptide, the C-terminal of the peptide, on a free amino or carboxyl group along the peptide chain, or at a plurality of these sites. Those peptides exhibit clinical usefulness for example in treating states of insulin resistance associated with pathologies such as type II diabetes.
    Type: Application
    Filed: March 3, 2003
    Publication date: October 30, 2003
    Inventors: Denis Gravel, Abdelkrim Habi, Thierry Abribat
  • Patent number: 6458764
    Abstract: The present invention relates to chimeric fatty body-GRF analogs with increased biological potency, their application as anabolic agents and in the diagnosis and treatment of growth hormone deficiencies. The chimeric fatty body-GRF analogs include an hydrophobic moiety (tail), and can be prepared, either by anchoring at least one hydrophobic tail to the GRF, in the chemical synthesis of GRF. The GRF analogs of the present invention are biodegradable, non-immunogenic and exhibit an improved anabolic potency with a reduced dosage and prolonged activity.
    Type: Grant
    Filed: September 3, 1999
    Date of Patent: October 1, 2002
    Assignee: Theratechnologies Inc.
    Inventors: Denis Gravel, Abdelkrim Habi, Paul Brazeau
  • Publication number: 20020016278
    Abstract: This invention relates to compositions for removing biofilms from contaminated surfaces. The compositions minimally comprise a detergent and a salt or a salt-forming acid. Preferably, the compositions comprise a detergent and a salt-forming acid, to provide salts and acids in equilibrium, in such a way that the biofilm is rapidly dismantled and removed in such an environment. The compositions may also comprise a bactericide, for destroying bacteria.
    Type: Application
    Filed: May 9, 2001
    Publication date: February 7, 2002
    Inventors: Jean Barbeau, Denis Gravel, Abdelkrim Habi